# US 2019/0376041 A1 · Reprogramming of cells to a new fate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376041 A1
- Document ID: US20190376041A1
- Status: Published application
- Kind: A1
- Application number: 16/387,305
- Filed: 2019-04-17
- Published: 2019-12-12
- Earliest claimed: 2010-06-14
- Assignees: The Scripps Research Institute
- Applicants: The Scripps Research Institute
- Inventors: Jem A. Efe; Janghwan Kim; Saiyong Zhu; Simon Hilcove; Sheng Ding
- Web page: https://patentgrep.com/patent/US20190376041A1

## CPC

- C12N 5/0676: {Pancreatic cells}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 35/33: Fibroblasts
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- C12N 5/0602: {Vertebrate cells}
- C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/0619: {Neurons}
- C12N 5/0623: {Stem cells}
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- C12N 15/85: for animal cells
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/605: Nanog
- C12N 2501/606: c-Myc
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/02: from embryonic cells
- C12N 2506/08: from cells of the nervous system
- C12N 2506/1307: from adult fibroblasts
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.

## Claims

### Claim at position 1

1-48. (canceled)

### Claim 49

A method for screening for small molecules that enhance conversion of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate, the method comprising:
(a) introducing a polynucleotide encoding an Oct4 polypeptide, and optionally one or more reprogramming factors comprising polynucleotides encoding a Klf4 polypeptide, a Sox2 polypeptide, or a c-Myc polypeptide, into a first non-pluripotent cell, or
contacting a first non-pluripotent cell with an Oct4 polypeptide, and optionally one or more reprogramming factors comprising a Klf4 polypeptide, a Sox2 polypeptide, or a c-Myc polypeptide;
(b) limiting the expression of endogenous Nanog in the cells from step (a) to a level substantially lower than the level of expression of endogenous Nanog in an induced pluripotent cell (iPSC), thereby generating a non-pluripotent intermediate cell;
(c) contacting the cells from step (b) with a library of different small molecules under conditions to generate a cell having a second non-pluripotent cell fate;
(d) screening the contacted cells from step (c) for characteristics of a second non-pluripotent cell fate;
(e) correlating the characteristics of a second non-pluripotent cell fate with a particular small molecule from the library, thereby identifying a small molecule that enhances conversion of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate.

### Claim 50 (depends on 49)

The method of claim 49, wherein step (b) further comprises contacting the non-pluripotent intermediate cell with a JAK inhibitor.

### Claim 51 (depends on 49)

The method of claim 49, wherein step (b) comprises eliminating exogenous LIF.

### Claim 52 (depends on 49)

The method of claim 49, wherein the cells in step (b) are exposed to media containing about 15% growth serum prior to contacting the cells with a small compound in step (c).

### Claim 53 (depends on 52)

The method of claim 52, wherein the cells exposed to media containing about 15% growth serum are subsequently exposured to media containing about 1% growth serum prior to contacting the cells with a small compound in step (c).

### Claim 54 (depends on 49)

The method of claim 49, wherein step (c) comprises culturing the cells in a chemically defined medium.

### Claim 55 (depends on 54)

The method of claim 54, wherein step (c) comprises culturing the cells in a serum-free, monolayer.

### Claim 56 (depends on 49)

The method of claim 49, wherein the first non-pluripotent cell is a fibroblast or a neural precursor cell.

### Claim 57 (depends on 49)

The method of claim 49, wherein the method is conducted in vitro.

### Claim 58 (depends on 49)

The method of claim 49, wherein the small molecule comprises ascorbic acid; a pathway modulator selected from the group consisting of a bone morphogenetic protein (BMP) pathway, a Hedgehog pathway, a Wnt pathway, a Notch pathway, and a TGFβ/activin pathway;
a calcium channel agonist; a Gαs activating agent, a cAMP analog; a GSK-3 inhibitor; and/or an histone deacetylase (HDAC) inhibitor.

### Claim 59 (depends on 58)

The method of claim 58, wherein the pathway modulator is an inhibitor.

### Claim 60 (depends on 58)

The method of claim 58, wherein the pathway modulator is an activator.

### Claim 61 (depends on 58)

The method of claim 58, wherein
(a) the BMP pathway modulator is BMP4 or LDN-193189
(b) the Hedgehog pathway modulator is GDC-0449
(c) the Wnt pathway modulator is Dkk-1 or Wnt5a
(d) the Notch pathway modulator is DAPT;
(e) the TGFβ/activin pathway modulator is A-83-01 or SB4313542;
(f) the calcium channel agonist is BayK 8644;
(g) the GSK3 inhibitor is CHIR99021 BIO; and/or
(h) the HDAC inhibitor is NaB.

### Claim 62

A composition for efficiently transdifferentiating an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate, the composition comprising:
(a) a non-pluripotent intermediate cell obtained by a method of
(i) introducing a polynucleotide encoding an Oct4 polypeptide, and optionally one or more reprogramming factors comprising polynucleotides encoding a Klf polypeptide, a Sox2 polypeptide, or a c-Myc polypeptide; or
contacting cells having a first non-pluripotent cell fate with an Oct4 polypeptide, and optionally one or more reprogramming factors comprising a Klf polypeptide, a Sox2 polypeptide, or a c-Myc polypeptide; and
(ii) limiting the expression of endogenous Nanog in the cells from step (i) to a level substantially lower than the level of expression of endogenous Nanog in an induced pluripotent cell (iPSC), thereby generating a non-pluripotent intermediate cell; and
(b) one or more of a growth factor, a cytokine, and/or a small molecule, wherein the one or more of a growth factor, a cytokine, and/or a small molecular are present in amounts effective to induce differentiation of the non-pluripotent intermediate cell into a cell having a second non-pluripotent cell fate.

### Claim 63 (depends on 62)

The composition of claim 62, wherein the composition further comprises a chemically defined medium.

### Claim 64 (depends on 63)

The composition of claim 63, wherein the chemically defined medium is serum-free.

### Claim 65 (depends on 62)

The composition of claim 62, wherein step (a)(ii) comprises eliminating exogenous LIF, a JAK inhibitor, a PI3K inhibitor, a CDK2 inhibitor, a CDK4 inhibitor, a glycolysis inhibitor, a Wnt inhibitor, or a combination thereof.

### Claim 66 (depends on 62)

The composition of claim 62, wherein the first non-pluripotent cell is a fibroblast or a neural precursor cell.

### Claim 67 (depends on 62)

The composition of claim 62, wherein the second non-pluripotent cell fate is a cardiomyocyte.

### Claim 68 (depends on 67)

The composition of claim 67, wherein the one or more of a growth factor, a cytokine, and/or a small molecule that induces differentiation comprises a GSK-3 inhibitor, a calcium channel agonist, a Gαs activating agent, a cAMP analog, and/or a BMP protein.

### Claim 69 (depends on 68)

The composition of claim 68, wherein the non-pluripotent intermediate cell from step (a)(ii) is contacted with a JAK inhibitor.

### Claim 70 (depends on 62)

The composition of claim 62, wherein the second non-pluripotent cell fate is a neural progenitor cell.

### Claim 71 (depends on 70)

The composition of claim 70, wherein the one or more of a growth factor, a cytokine, and/or a small molecule that induces differentiation comprises FGF2, FGF4, and EGF.

### Claim 72 (depends on 71)

The composition of claim 71, wherein the non-pluripotent intermediate cell from step (a)(ii) is contacted with a Wnt inhibitor, a JAK inhibitor, or both a Wnt inhibitor and a JAK inhibitor.

### Claim 73 (depends on 62)

The composition of claim 62, wherein the second non-pluripotent cell fate is an induced definitive endoderm (iDE) cell.

### Claim 74 (depends on 73)

The composition of claim 73, wherein the one or more of a growth factor, a cytokine, and/or a small molecule that induces differentiation comprises a GSK-3 inhibitor, an HDAC inhibitor, and/or a TGFP/Activin/Nodal family member.

### Claim 75 (depends on 62)

The composition of claim 62, wherein the second non-pluripotent cell fate is a pancreatic beta cell.

### Claim 76 (depends on 75)

The composition of claim 75, wherein the one or more of a growth factor, a cytokine, and/or a small molecule that induces differentiation comprises:
(a) GSK-3 inhibitor, an HDAC inhibitor, and/or a TGFβ/Activin/Nodal family member;
(b) FGF7, retinoic acid (RA), a Hedgehog pathway inhibitor, a BMP inhibitor, and/or a TGFβ/ALK5 inhibitor;
(c) EGF and/or a Notch inhibitor; and
(d) bFGF, nicotinamide, and/or extendin-4.
